Matthew Snape

• An increase in Accident and Emergency presentations for Adverse Events Following Immunisation after introduction of the group B meningococcal vaccine : an observational study.

  Nainani V. et al, (2017), Archives of Disease in Childhood

• Emerging clinical experience with vaccines against group B meningococcal disease

  Snape MD. and Wilkins AL., (2017), Vaccine

• Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].

  Iro MA. et al, (2017), Vaccine, 35, 3279 - 3279

• Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.

  Trück J. et al, (2017), Vaccine, 35, 2701 - 2708

• Immune responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 year

  Winslow RL. et al, (2017), Journal of the American Medical Association

• Persistence of immune responses induced by Ebola virus vaccines.

  Snape MD., (2017), The Lancet Global Health

• High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine.

  O'Connor D. et al, (2017), Genome Med, 9, 11 - 11

• Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

  Iro MA. et al, (2017), Vaccine, 35, 395 - 402

• Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule.

  Trück J. et al, (2016), Pediatr Infect Dis J

• Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy.

  Pace D. et al, (2016), Vaccine, 34, 6350 - 6357

• Schedules for Pneumococcal Vaccination of Preterm Infants: An RCT.

  Kent A. et al, (2016), Pediatrics, 138

• Immunisation of the immunocompromised child.

  Pinto MV. et al, (2016), J Infect, 72 Suppl, S13 - S22

• The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy.

  Trück J. et al, (2016), The Pediatric infectious disease journal, 35, 787 - 793

• Attitudes towards antenatal vaccination, Group B streptococcus and participation in clinical trials: Insights from focus groups and interviews of parents and healthcare professionals

  McQuaid F. et al, (2016), Vaccine

• Factors influencing women’s attitudes towards antenatal vaccines, Group B streptococcus and clinical trial participation in pregnancy: An on-line survey.

  Snape MD. and voysey M., (2016), BMJ Open

• Lymphocyte subpopulations in premature infants: an observational study.

  Kent A. et al, (2016), Archives of disease in childhood. Fetal and neonatal edition

• Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells.

  Voysey M. et al, (2016), Vaccine, 34, 1657 - 1664

• Immunogenicity and Reactogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial

  Snape MD. et al, (2016), Journal of the American Medical Association

• Control of invasive meningococcal disease: is it achievable?

  Marshall H. et al, (2016), Int J Evid Based Healthc, 14, 3 - 14

• Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.

  Lazarus R. et al, (2016), PLoS One, 11

• Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey.

  Voysey M. et al, (2015), Vaccine

• Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study

  Turner PJ. et al, (2015), BMJ, h6291 - h6291

• Persistence of bactericidal antibodies following infant serogroup B meningococcal immunization (4CMenB) and booster dose response at 12, 18 or 24 months of age

  Snape MD. et al, (2015), Pediatric Infectious Disease Journal

• Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

  Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52

• Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers.

  McCullagh D. et al, (2015), BMJ Open, 5

• Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months.

  McQuaid F. et al, (2015), CMAJ, 187, E215 - E223

• Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial.

  Hamaluba M. et al, (2015), Lancet Infect Dis, 15, 405 - 414

• Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial.

  Iro MA. et al, (2015), Lancet Infect Dis, 15, 172 - 180

• Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.

  Thebault S. et al, (2015), PLoS One, 10

• Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.

  Pace D. et al, (2015), BMJ (Clinical research ed.), 350, h1554 - h1554

• A cross-sectional observational study of pneumococcal carriage in children, their parents, and older adults following the introduction of the 7-valent pneumococcal conjugate vaccine.

  Hamaluba M. et al, (2015), Medicine (Baltimore), 94

• Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

  Read RC. et al, (2014), Lancet, 384, 2123 - 2131

• Randomized clinical trial to evaluate the immunogenicity of quadrivalent meningococcal conjugate and polysaccharide vaccines in adults in the United kingdom.

  Ramasamy MN. et al, (2014), Clin Vaccine Immunol, 21, 1164 - 1168

• Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age.

  McQuaid F. et al, (2014), Pediatr Infect Dis J, 33, 760 - 766

• Attitudes towards vaccination against group B streptococcus in pregnancy.

  McQuaid F. et al, (2014), Arch Dis Child, 99, 700 - 701

• Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine

  O'Connor D. et al, (2014), Vaccine, 32, 3424 - 3430

• Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine.

  O'Connor D. et al, (2014), Vaccine, 32, 3424 - 3430

• Will booster doses be required for serogroup B meningococcal vaccine?

  McQuaid F. and Snape MD., (2014), Expert Rev Vaccines, 13, 313 - 315

• Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action.

  Barker CI. and Snape MD., (2014), Lancet Infect Dis, 14, 227 - 238

• Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial.

  Trück J. et al, (2014), PLoS One, 9

• Evaluation of the induction of immune memory following infant immunisation with serogroup C Neisseria meningitidis conjugate vaccines--exploratory analyses within a randomised controlled trial.

  Khatami A. et al, (2014), PLoS One, 9

• Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: An observer-blind, phase 3 randomised clinical trial

  Read RC. et al, (2014), The Lancet, 384, 2123 - 2131

• Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

  Hoschler K. et al, (2014), Clin Infect Dis, 58, 181 - 187

• Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose.

  Snape MD. et al, (2013), CMAJ, 185, E715 - E724

• Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.

  Rodgers GL. et al, (2013), Vaccine, 31, 4765 - 4774

• Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: a follow-on study to a randomized clinical trial.

  Snape MD. et al, (2013), Pediatr Infect Dis J, 32, 1116 - 1121

• Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.

  de Whalley PC. et al, (2013), Arch Dis Child, 98, 686 - 691

• Bactericidal antibody persistence 2 years after immunization with 2 investigational serogroup B meningococcal vaccines at 6, 8 and 12 months and immunogenicity of preschool booster doses: A follow-on study to a randomized clinical trial

  Snape MD. et al, (2013), Pediatric Infectious Disease Journal, 32, 1116 - 1121

• The price of prevention: what now for immunisation against meningococcus B?

  Moxon R. and Snape MD., (2013), Lancet, 382, 369 - 370

• A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

  Martin NG. and Snape MD., (2013), Expert Rev Vaccines, 12, 837 - 858

• Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis serogroups A, C, y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom

  Blanchard-Rohner G. et al, (2013), Pediatric Infectious Disease Journal, 32, 768 - 776

• Seroprevalence and placental transmission of maternal antibodies specific for Neisseria meningitidis Serogroups A, C, Y and W135 and influence of maternal antibodies on the immune response to a primary course of MenACWY-CRM vaccine in the United Kingdom.

  Blanchard-Rohner G. et al, (2013), Pediatr Infect Dis J, 32, 768 - 776

• Genetic material should be routinely collected in clinical vaccine trials--high consent rates can be achieved across all age groups.

  Trück J. et al, (2013), Vaccine, 31, 2744 - 2748

• UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure.

  Yates TA. et al, (2013), Arch Dis Child, 98, 429 - 433

• Phase II study of a three-dose primary vaccination course of DTPa-IPV/Hib-MenC-TT followed by a 12-month Hib-MenC-TT booster in healthy infants.

  Khatami A. et al, (2013), Pediatr Infect Dis J, 32, 675 - 681

• The B-cell response to a primary and booster course of MenACWY-CRM₁₉₇ vaccine administered at 2, 4 and 12 months of age.

  Blanchard-Rohner G. et al, (2013), Vaccine, 31, 2441 - 2448

• The beginning of the end for serogroup B meningococcus?

  Snape MD. and Pollard AJ., (2013), Lancet, 381, 785 - 787

• The beginning of the end for serogroup B meningococcus?

  Snape MD. and Pollard AJ., (2013), The Lancet, 381, 785 - 787

• Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action

  Barker CIS. and Snape MD., (2013), The Lancet Infectious Diseases

• Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine.

  Blanchard-Rohner G. et al, (2012), Vaccine, 30, 4153 - 4159

• T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.

  Lambe T. et al, (2012), Pediatr Infect Dis J, 31, e86 - e91

• The challenge of post-implementation surveillance for novel meningococcal vaccines.

  Snape MD. et al, (2012), Vaccine, 30 Suppl 2, B67 - B72

• Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations

  Khatami A. et al, (2012), Vaccine, 30, 2831 - 2838

• Immunogenicity of polysaccharide and conjugate quadrivalent meningococcal ACYW-135 vaccines in healthy adult volunteers – a randomised clinical trial

  Ramasamy MN. et al, (2012), Clinical Microbiology and Infection. Supplement, 18

• Single nucleotide polymorphisms in the toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine

  Moore CE. et al, (2012), Clinical and Vaccine Immunology, 19, 295 - 303

• Single nucleotide polymorphisms in the Toll-like receptor 3 and CD44 genes are associated with persistence of vaccine-induced immunity to the serogroup C meningococcal conjugate vaccine.

  Moore CE. et al, (2012), Clin Vaccine Immunol, 19, 295 - 303

• H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.

  Walker WT. et al, (2012), Clin Infect Dis, 54, 661 - 669

• Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial.

  Gossger N. et al, (2012), JAMA, 307, 573 - 582

• T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization with Pandemic H1N1 Influenza Vaccine, and Response to Revaccination with Seasonal Trivalent-inactivated Influenza Vaccine

  Lambe T. et al, (2012), Pediatric Infectious Disease Journal, 31, e86 - e91

• Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations

  Khatami A. et al, (2012), Vaccine, 30, 2831 - 2838

• Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study

  Khatami A. et al, (2012), Pediatr Infect Dis J, 31, 1069 - 1073

• Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood.

  Khatami A. et al, (2011), Clin Vaccine Immunol, 18, 2038 - 2042

• A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.

  de Whalley P. et al, (2011), Health Technol Assess, 15, v - 128

• Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine

  De Whalley PCS. et al, (2011), Pediatric Infectious Disease Journal, 30

• Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.

  de Whalley PC. et al, (2011), Pediatr Infect Dis J, 30, e203 - e208

• Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.

  Andrews NJ. et al, (2011), Vaccine, 29, 7913 - 7919

• Fine with five? Shorter antibiotic courses for childhood meningitis.

  Snape MD. and Kelly DF., (2011), Lancet, 377, 1809 - 1810

• Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines

  Walker W. et al, (2011), INFLUENZA AND OTHER RESPIRATORY VIRUSES, 5, 332 - 333

• Immunisation of adolescents in the UK.

  Kale AR. and Snape MD., (2011), Arch Dis Child, 96, 492 - 495

• A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.

  Su EL. and Snape MD., (2011), Expert Rev Vaccines, 10, 575 - 588

• Persistence of immunity following a booster dose of Haemophilus influenzae type B-Meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial.

  Khatami A. et al, (2011), Pediatr Infect Dis J, 30, 197 - 202

• Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines

  Andrews NJ. et al, (2011), Vaccine

• A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children

  de Whalley P. et al, (2011), Health Technology Assessment, 15

• MEMORY B CELL RESPONSES FOLLOWING IMMUNISATION WITH POLYSACCHARIDE AND CONJUGATE QUADRIVALENT MENINGOCOCCAL ACYW135 VACCINES IN HEALTHY ADULT VOLUNTEERS

  Maheshi R. et al, (2010), JOURNAL OF INFECTION, 61, 517 - 517

• Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.

  Snape MD. et al, (2010), Pediatr Infect Dis J, 29, e80 - e90

• Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy.

  Findlow J. et al, (2010), Clin Infect Dis, 51, 1127 - 1137

• Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial.

  Snape MD. et al, (2010), Pediatr Infect Dis J, 29, e71 - e79

• Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.

  Waddington C. et al, (2010), Health Technol Assess, 14, 1 - 130

• Safety and immunogenicity of AS03 <inf>B</inf> adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study

  Waddington CS. et al, (2010), BMJ (Online), 340

• Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.

  Waddington CS. et al, (2010), BMJ, 340

• Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans.

  Blanchard-Rohner G. et al, (2009), Blood, 114, 4998 - 5002

• Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.

  Leroux-Roels I. et al, (2009), Vaccine, 27, 6918 - 6925

• Future of flu vaccines. Expediting clinical trials in a pandemic.

  Pollard AJ. et al, (2009), BMJ, 339

• Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine.

  Kelly DF. et al, (2009), Immunology, 127, 134 - 143

• Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.

  Perrett KP. et al, (2009), Pediatr Infect Dis J, 28, 186 - 193

• Demonstration of immunologic memory using serogroup C meningococcal glycoconjugate vaccine.

  Snape MD. et al, (2009), Pediatr Infect Dis J, 28, 92 - 97

• A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial.

  Pace D. et al, (2008), Arch Dis Child, 93, 963 - 970

• Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study.

  Snape MD. et al, (2008), BMJ, 336, 1487 - 1491

• The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response.

  Blanchard Rohner G. et al, (2008), J Immunol, 180, 2165 - 2173

• Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.

  Snape MD. et al, (2008), JAMA, 299, 173 - 184

• A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.

  Pace D. et al, (2007), Pediatr Infect Dis J, 26, 1057 - 1059

• Serogroup C meningococcal glycoconjugate vaccine in adolescents: persistence of bactericidal antibodies and kinetics of the immune response to a booster vaccine more than 3 years after immunization.

  Snape MD. et al, (2006), Clin Infect Dis, 43, 1387 - 1394

• African tick bite fever.

  Snape MD. and Pollard AJ., (2006), Lancet Infect Dis, 6

• No evidence for capsule replacement...and Wales - Authors' Reply

  Snape M. and Pollard A., (2006), Lancet Infectious Diseases, 6, 617 - 618

• No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales - Authors' reply

  Snape MD. and Pollard AJ., (2006), LANCET INFECTIOUS DISEASES, 6, 617 - 618

• CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells

  Kelly DF. et al, (2006), Blood, 108, 2642 - 2647

• Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine.

  Snape MD. et al, (2005), Pediatr Infect Dis J, 24, 128 - 131

• Meningococcal polysaccharide-protein conjugate vaccines.

  Snape MD. and Pollard AJ., (2005), Lancet Infect Dis, 5, 21 - 30

• Where next? The emergence of hypervirulent W meningococcus in the Netherlands

  Snape MD. and broad J., lancet public health

• Quadrivalent meningococcal polysaccharide and conjugate vaccines: Interim results of a clinical trial in adult volunteers

  Ramasamy MN. et al, Journal of Infection, 61

• Plasma cell and memory B cell responses following immunisation with polysaccharide and conjugate quadrivalent meningococcal ACYW135 vaccines in healthy adult volunteers.

  Ramasamy MN. et al

• Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease

  Pollard AJ. et al

Recent Publications

• An increase in Accident and Emergency presentations for Adverse Events Following Immunisation after introduction of the group B meningococcal vaccine : an observational study.

  Nainani V. et al, (2017), Archives of Disease in Childhood

• Emerging clinical experience with vaccines against group B meningococcal disease

  Snape MD. and Wilkins AL., (2017), Vaccine

• Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].

  Iro MA. et al, (2017), Vaccine, 35, 3279 - 3279

• Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13.

  Trück J. et al, (2017), Vaccine, 35, 2701 - 2708

• Immune responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 year

  Winslow RL. et al, (2017), Journal of the American Medical Association